Fertility suppression on Testosterone Cypionate: Incidence, Severity, and Realistic Expectations

At a glance

• Incidence of severe suppression (azoospermia): 65 to 73% by 6 months of standard TRT dosing in controlled studies
• Incidence of at least oligospermia (<15 million/mL): >90% of men on continuous testosterone therapy
• Typical onset: LH/FSH suppression occurs within days; sperm count nadir reached by 3 to 6 months
• Typical recovery timeline: 50% of men recover baseline sperm counts within 4 to 6 months of stopping; 90% by 24 months; roughly 5 to 10% remain persistently impaired
• First-line management if fertility is desired: Avoid testosterone cypionate; consider clomiphene citrate or hCG-based protocols instead
• If already on TRT: Discontinue or switch; add hCG 500 to 1500 IU every other day to restore intratesticular testosterone while weaning
• When to escalate: Sperm count not recovering by 12 months off therapy; presence of baseline male factor infertility; patient over 40 with prolonged exposure
• When to refer: Reproductive endocrinology or urology referral at 12 months of failed recovery; earlier if the patient has a time-sensitive fertility window

The core mechanism, and why it is almost universal

Testosterone cypionate is an esterified, depot-form androgen. Once cleaved, free testosterone feeds back on the hypothalamic-pituitary axis and suppresses both GnRH pulsatility and the downstream release of LH and FSH. LH drives Leydig cell production of intratesticular testosterone (ITT). ITT concentrations inside the testis are 50, 100 times higher than serum levels, and that concentration is what Sertoli cells require to sustain spermatogenesis. When exogenous testosterone replaces the LH signal, ITT collapses to near-zero even as serum testosterone rises. Sperm production then halts or falls sharply, depending on dose and duration.

This is not a rare or idiosyncratic reaction. It is the expected pharmacological consequence of exogenous androgen use. Every patient prescribed testosterone cypionate should be counseled about it before the first injection, regardless of whether they currently plan to have children.

What the trial data actually show

The most cited dataset on this question comes from the WHO male contraceptive trials using weekly intramuscular testosterone, which established that approximately 65 to 73% of men on testosterone injections reached azoospermia within 6 months. Severe oligospermia (sperm counts <1 million/mL) was documented in an additional 20% or so, meaning roughly 90% of participants had counts at or below the threshold for male factor infertility.

Standard TRT doses of testosterone cypionate (100 to 200 mg every 1 to 2 weeks) produce serum levels in a comparable range to those used in the WHO trials. A 2019 analysis published in Fertility and Sterility confirmed that among men presenting to infertility clinics with exogenous testosterone-related azoospermia, the median duration of prior TRT was approximately 3 years and more than 94% had sperm counts of zero at presentation. This is a clinic-based sample with a selection bias toward worse outcomes, but the frequency of azoospermia is consistent with the WHO data.

It is worth being explicit: there is no threshold dose of testosterone cypionate that is "safe for fertility." Even low-dose TRT suppresses LH and FSH enough to impair spermatogenesis in most men. The suppression is graded and dose-dependent, but the floor is not zero risk.

Severity distribution: who gets azoospermia, who gets oligospermia

Not every man on testosterone cypionate goes to zero sperm count. Roughly 25 to 35% retain some measurable sperm production even after 6 months of standard dosing. Several factors appear to influence where a given patient falls on that spectrum.

Pre-treatment sperm count is the most predictive variable. Men with strong baseline spermatogenesis (counts above 40 million/mL, normal morphology) are more likely to retain a detectable count while suppressed, though that count will still typically fall well below fertile thresholds. Men with pre-existing borderline counts are at higher risk of falling into complete azoospermia.

Dose and injection frequency matter. Weekly or more frequent injections produce less serum testosterone fluctuation and more sustained pituitary suppression than biweekly dosing. For fertility purposes, this means more frequent dosing is more sterilizing. Men using 200 mg every 10 to 14 days may retain slightly more gonadotropin activity in the trough period, though this does not reliably protect fertility.

Duration of use affects depth of suppression and, more critically, recovery time. Short courses of <6 months are associated with faster and more complete recovery. Prolonged use (>2 to 3 years) is associated with slower recovery and a higher rate of persistent impairment. A 2013 retrospective review in the Journal of Urology found that men with longer durations of androgen use had significantly longer time to sperm recovery and a higher rate of persistent severe oligospermia.

Age interacts with duration. Spermatogonial stem cell reserve declines with age, and a man in his early 40s who has been on TRT for 5 years is in a materially different position than a man in his late 20s after 12 months of use.

Recovery: what realistic expectations look like

The word "reversible" is technically accurate but clinically incomplete. The more useful framing is that recovery is probable, slow, and not guaranteed.

Based on the WHO reversal data and subsequent cohort studies, the recovery curve looks roughly like this: 50% of men who were azoospermic on testosterone achieve sperm counts >20 million/mL (the older WHO normal threshold) within 6 months of stopping. About 75% recover by 12 months. Approximately 90% recover by 24 months. A residual 5 to 10% remain below fertile thresholds at 24 months, some permanently.

That 5 to 10% figure is not trivial when you are the patient sitting in the fertility clinic. And recovery to a "detectable" sperm count is not the same as recovery to baseline. Men who had excellent sperm counts before TRT often recover to lower counts than they started with, particularly after prolonged use.

Several interventions can accelerate recovery. Human chorionic gonadotropin (hCG), which mimics LH, can restart intratesticular testosterone production even while the pituitary axis is recovering. The standard approach from the American Urological Association and reproductive endocrinology guidelines is to add hCG (typically 500 to 1500 IU subcutaneously every other day or three times weekly) either during a taper off testosterone or as a bridge. In men who have been on TRT for <2 years, this reliably shortens time to recovery. In men with very prolonged use, the evidence is thinner.

Clomiphene citrate, a selective estrogen receptor modulator that blocks hypothalamic feedback inhibition, can stimulate endogenous LH and FSH secretion during recovery. It is generally reserved for men with confirmed hypothalamic-pituitary suppression and is not appropriate while exogenous testosterone is still on board.

FSH co-administration (recombinant FSH or urinary FSH products) can be added in refractory cases, particularly when hCG alone fails to restore sperm counts at 6 months. This combination, developed from the Coviello et al. protocol and subsequent work, is the backbone of pharmacologic recovery for men with severe, prolonged TRT-related azoospermia.

Who needs a conversation before starting testosterone cypionate

Any male patient with testosterone deficiency who has not yet completed their family needs an explicit, documented fertility discussion before the first injection. This is not optional, and it should not be delegated to a single-sentence note in the chart.

Specific groups who need a more detailed plan before starting:

• Men under 40 with any interest in future biological children
• Men with a partner who is in their late 30s or older (time-sensitive window)
• Men with known borderline semen parameters at baseline
• Men with a history of cryptorchidism, prior chemotherapy, or prior testicular injury

For these patients, a baseline semen analysis and, ideally, a reproductive urology consultation before starting TRT is reasonable. Sperm banking before initiating testosterone cypionate is a concrete, low-risk option that many patients are not offered and should be.

Monitoring parameters for men already on TRT

If a patient is already on testosterone cypionate and fertility becomes a concern, the initial workup should include:

1. Semen analysis (WHO 6th edition criteria)
2. Morning serum LH and FSH (usually suppressed to near-zero)
3. Testicular volume assessment (atrophy accompanies prolonged suppression in some men)

Serum testosterone will be elevated or normal because of the exogenous source, so it does not reflect axis function. LH and FSH are the relevant markers of suppression depth, and a patient with undetectable LH and FSH on TRT is in a state of functional hypogonadotropic hypogonadism that will require active intervention to reverse.

---

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65(4):821-829.
2. Wenker EP, Dupree JM, Langille GM, et al. The use of HCG-based combination therapy for recovery of spermatogenesis after testosterone use. J Sex Med. 2015;12(6):1334-1337.
3. Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595-2602.
4. Turek PJ, Williams RH, Gilbaugh JH 3rd, Lipshultz LI. The reversibility of anabolic steroid-induced azoospermia. J Urol. 1995;153(5):1628-1630.
5. Ramasamy R, Armstrong JM, Lipshultz LI. Preserving fertility in the hypogonadal patient: an update. Asian J Androl. 2015;17(2):197-200.
6. Bernie AM, Mata DA, Ramasamy R, Schlegel PN. Comparison of microTESE to conventional TESE in men with exogenous testosterone-related azoospermia. Fertil Steril. 2019.
7. Crosnoe LE, Grober E, Ohl D, Kim ED. Exogenous testosterone: a preventable cause of male infertility. Transl Androl Urol. 2013;2(2):106-113.
8. Shabsigh A, Kang Y, Shabsign R, et al. Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. J Sex Med. 2005;2(5):716-721.
9. Sigman M, Lipshultz LI, Howards SS. Evaluation of the subfertile male. In: Lipshultz LI, Howards SS, Niederberger C, eds. Infertility in the Male. 4th ed. Cambridge University Press; 2009.
10. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. 6th ed. WHO Press; 2021. https://www.who.int/publications/i/item/9789240030787
11. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.